What's new? Log in Free sign up

LakeShore Biopharma (LSB)

Company Profile

Company profile

Ticker

LSB, LSBPW

Exchange

Website

www.ysbiopharm.com

CEO

Mr. Wang Xu

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

YishengBio Co., Ltd, YS Biopharma Co., Ltd.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

LSB stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

Report of Foreign Private Issuer

Report of Foreign Private Issuer

LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan

Report of Foreign Private Issuer

Report of Foreign Private Issuer

LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine

Report of Foreign Private Issuer

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

Current report (foreign) (amended)

Latest ownership filings

Wong Fung Ching

Financial summary

Financial statements Chart LSB financial data

Quarter (USD)	Mar 24	Mar 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 24	Mar 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2024

LSB institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	20	24	-16.7%
Opened positions	1	1	–
Closed positions	5	14	-64.3%
Increased positions	0	0
Reduced positions	1	2	-50.0%

13F shares	Current	Prev Q	Change
Total value	375.84 mm	287.02 mm	+30.9%
Total shares	141.46 mm	141.23 mm	+0.2%
Total puts	0.00	0.00
Total calls	499.60 k	1.13 mm	-55.7%
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Wong Fung Ching	98.36 mm	$39.44 mm	0.0%
Zhang /MD Yi	38.97 mm	$15.75 mm	0.0%
LMR Partners	1.05 mm	$83.57 mm	NEW
Valliance Asset Management	750.00 k	$59.55 mm	0.0%
Jane Street	498.30 k	$39.57 mm	0.0%
Finepoint Capital	490.00 k	$48.51 mm	0.0%
Bracebridge Capital	232.32 k	$18.45 mm	0.0%
Ovata Capital Management	150.00 k	$14.85 mm	0.0%
Calamos Advisors	146.04 k	$14.46 mm	0.0%
Q Global Advisors	130.60 k	$10.00 k	0.0%

Largest transactions	Shares	Bought/sold	Change
LMR Partners	1.05 mm	+1.05 mm	NEW
BFAM Partners	0.00	-550.00 k	EXIT
Cowen And	0.00	-212.85 k	EXIT
Meteora Capital	0.00	-25.00 k	EXIT
Two Sigma Securities	0.00	-17.40 k	EXIT
SkyView Investment Advisors	0.00	-12.21 k	EXIT
Walleye Capital	95.03 k	-4.88 k	-4.9%
Proequities	0.00	0.00
Deutsche Bank AG - Registered Shares	0.00	0.00
D. E. Shaw & Co.	100.00 k	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's Pre-Market Session

LakeShore Biopharma Sees FY25 Revenues To Be Between RMB 665 Million - RMB 700 Million, Indicating Growth Of 16%-22% YoY

FY2025 Guidance UpdateFor the full FY2025, the Company expects total revenues to be between RMB 665 million and RMB 700 million, indicating a growth of 16% to 22% year-over-year. The Company also projects Adjusted EBITDA

12 Health Care Stocks Moving In Monday's Pre-Market Session

Reported Earlier, LakeShore Biopharma Takes Decisive Action In Response To Criminal Allegations Against Former Chairman, Yi Zhang

Press releases

From Benzinga Pro

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoYAchieved gross profit of RMB 307.3 million, a growth of 39.1% YoYGross margin increased to 82.6% from 80.9% in the same period of FY2024Total

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a leading global biopharmaceutical company focused on the innovation and production of

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.